Hypereosinophilic syndrome: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
|||
| Line 1: | Line 1: | ||
== Background == |
== Background == |
||
*Idiopathic eosinophilia persisting for more than 6 months without identifiable cause |
*Idiopathic [[eosinophilia]] persisting for more than 6 months without identifiable cause |
||
===Pathophysiology=== |
===Pathophysiology=== |
||
Latest revision as of 17:25, 5 May 2025
Background
- Idiopathic eosinophilia persisting for more than 6 months without identifiable cause
Pathophysiology
- Mutation in PDGFRA and FIP1L1 in some cases, causes a tyrosine kinase mutation
Clinical Manifestations
- Eosinophilia with cardiomyopathy, skin lesions, thromboembolism, pulmonary disease, neuropathy, hepatosplenomegaly, reduced ventricular size, and eczema
Differential Diagnosis
- Refer to Eosinophilia
Diagnosis
- Molecular testing for PDGFRA and FIP1L1
Management
- Steroids
- +/- mepolizumab for steroid-sparing
- +/- imatinib if PDGFRA/FIPL1 positive
Prognosis
- Progressive and fatal
